- Home
- AVT vs PTGX Comparison
AVT vs PTGX Comparison
Compare AVT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVT
- PTGX
- Stock Information
- Founded
- AVT 1921
- PTGX 2006
- Country
- AVT United States
- PTGX United States
- Employees
- AVT N/A
- PTGX N/A
- Industry
- AVT Electronic Components
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- AVT Technology
- PTGX Health Care
- Exchange
- AVT Nasdaq
- PTGX Nasdaq
- Market Cap
- AVT 4.3B
- PTGX 4.0B
- IPO Year
- AVT N/A
- PTGX 2016
- Fundamental
- Price
- AVT $48.45
- PTGX $78.62
- Analyst Decision
- AVT Sell
- PTGX Strong Buy
- Analyst Count
- AVT 3
- PTGX 9
- Target Price
- AVT $49.33
- PTGX $78.11
- AVG Volume (30 Days)
- AVT 889.5K
- PTGX 1.6M
- Earning Date
- AVT 10-29-2025
- PTGX 10-31-2025
- Dividend Yield
- AVT 2.72%
- PTGX N/A
- EPS Growth
- AVT N/A
- PTGX N/A
- EPS
- AVT 2.70
- PTGX 0.80
- Revenue
- AVT $22,495,174,000.00
- PTGX $209,180,000.00
- Revenue This Year
- AVT $5.60
- PTGX N/A
- Revenue Next Year
- AVT $5.99
- PTGX $142.86
- P/E Ratio
- AVT $17.93
- PTGX $97.73
- Revenue Growth
- AVT N/A
- PTGX N/A
- 52 Week Low
- AVT $39.22
- PTGX $33.31
- 52 Week High
- AVT $57.68
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- AVT 34.74
- PTGX 61.88
- Support Level
- AVT $46.73
- PTGX $73.08
- Resistance Level
- AVT $52.81
- PTGX $79.00
- Average True Range (ATR)
- AVT 1.39
- PTGX 2.39
- MACD
- AVT -0.35
- PTGX -0.24
- Stochastic Oscillator
- AVT 25.74
- PTGX 93.42
About AVT Avnet Inc.
Avnet Inc is an electronic component technology distributor and solutions provider. It serves customers from startups and mid-sized businesses to enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). The group operates in the Electronic Components segment and supports high and medium-volume customers to markets, sells, and distributes electronic components, and the Farnell segment supports lower-volume customers that need electronic components quickly to develop, prototype, and test their products. Its geographic regions are the Americas, EMEA, and Asia.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.